Mainstream

Rigel Receives Orphan Drug Designation By The Fda For Its Myelodysplastic Syndrome Treatment

Rigel receives orphan drug designation by the FDA for its myelodysplastic syndrome treatment

Rigel receives orphan drug designation by the FDA for its myelodysplastic syndrome treatment

Post ContentriglRead More

You might also be interested in reading CLARITY Act Faces Growing Scrutiny as Senate Markup Begins.

January 9, 2025
In Mainstream